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Abstract
Mesenchymal stem cells (MSCs) represent an attractive
cell type for research and therapy due to their ability
to proliferate, differentiate, modulate immune
reactions, and secrete trophic factors. MSCs exist in a
multitude of tissues, including bone marrow, umbilical
cord, and adipose tissues. Moreover, MSCs have
recently been isolated from the liver. Compared with
other MSC types, liver-derived human MSCs (LHMSCs)
possess general morphologies, immune functions, and
differentiation capacities. Interestingly, LHMCSs
produce higher levels of pro-angiogenic, anti-
inflammatory, and anti-apoptotic cytokines than those
of bone marrow-derived MSCs. Thus, these cells may
be a promising therapeutic source for liver diseases.
This paper summarizes the biological characteristics of
LHMSCs and their potential benefits and risks for the
treatment of liver diseases.
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Background
The liver is involved in regulation of several major
physiological processes, such as glycogen storage, lipid
metabolism, plasma protein secretion, and xenobiotic
detoxification [1]. Liver dysfunction and failure can have
diverse etiologies. Orthotropic liver transplantation
(OLT) is considered the most suitable therapeutic option
for patients with liver failure. However, it is severely
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limited by organ shortages, high expense, graft rejection,
and the requirement for long-term immunosuppression.
Cell-based therapy has been proposed as a potential
alternative to OLT [2–4]. Over the past decade, mesen-
chymal stem cells (MSCs) have attracted considerable at-
tention. MSCs are defined as adherent multipotent
fibroblast-type stem cells with the ability to differentiate
into mesodermal and ectodermal cells [5, 6]. Unlike
other types of stem cells (such as embryonic stem cells
and induced pluripotent stem cells), MSCs have low im-
munogenicity and marked immunomodulatory effects,
which reduce the probability of immune rejection [7–9].
Moreover, MSCs are resistant to reactive oxygen species
in vitro, reduce oxidative stress in recipient mice, and
accelerate repopulation of hepatocytes after liver damage
[10]. Therefore, pre-clinical and clinical trials have been
performed to determine the therapeutic potential of
MSCs [11, 12].
MSCs are distributed extensively and were initially
identified in bone marrow [13] and then in various tis-
sues, including the lung, umbilical cord, and adipose tis-
sue [14, 15]. The liver is a novel reservoir of MSCs.
Liver-derived human MSCs (LHMSCs) possess proper-
ties similar to those of MSCs from other tissues, includ-
ing proliferative, differentiation, and immunomodulatory
capacities. However, LHMSCs are different in certain re-
spects, particularly in terms of their biomarkers and bio-
logical functions. This review focuses on hepatic
differentiation of LHMSCs and their application in liver
disorders, opening a new path toward further studies.
Isolation and culture of LHMSCs
LHMSCs were first isolated from first-trimester fetal
livers [16] and later from second-trimester fetal livers
[17]. To ensure the safety, quality, and identity of cell
products, a standardized procedure in compliance with
current Good Manufacturing Practices has been formu-
lated [18]. Briefly, disrupted liver tissue is harvested
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using a homogenizer following removal of adjacent tis-
sues. Then, mononuclear cells are isolated by density-
gradient centrifugation and cultured in Dulbecco’s modi-
fied Eagle’s medium with 15 % fetal bovine serum.
The fetal origin of MSCs raises both ethical and safety
issues. Thus, there was much enthusiasm over the isola-
tion of MSCs from adult tissues, which develop and
maintain their own stem cell pools. Evidence for the
presence of MSCs in the adult liver has accumulated.
Najimi et al. [19] successfully obtained adult liver-
derived human MSCs by enzymatic disaggregation of
adult human liver and the elimination of hepatocytes
and other liver cell types. Moreover, Pan et al. [20] re-
ported that these cells are likely a resident population
rather than bone marrow-derived cells.
Characterization of LHMSCs
In terms of morphology, cultured LHMSCs exhibit an
elongated spindle shape with ovoid nuclei (Fig. 1), as
well as stem cell properties, including positivity for stem
cell markers (vimentin and nestin) and MSC markers
(CD29, CD73, CD44, CD90, CD105, and CD166) [21].
However, LHMSCs are negative for hematopoietic stem
cell markers (CD34, CD45, CD117), suggesting that
these cells are not of hematopoietic origin [19, 22].
Compared with bone marrow-derived MSCs (BMMSCs),
the expression of CD105, a marker used to evaluate the
differentiation status of MSCs [23], is lower in LHMSCs.
This observation suggests that LHMSCs may be at a
more advanced stage of differentiation. Interestingly,
LHMSCs express CD26, albumin, CK8, and CK18, indi-
cating a partial commitment toward hepatic cell differ-
entiation [21, 22, 24]. Similar to other MSCs, LHMSCs
have low immunogenicity due to the absence of major
histocompatibility complex (MHC) class II (human
leukocyte antigen (HLA)-DP, -DQ, and -DR) antigens,
FAS ligand or costimulatory molecules with the excep-
tion of MHC class I antigens [25, 26].
Similar to MSCs from other tissues, LHMSCs have the
capacity for self-renewal, multipotent differentiation, and
immunosuppression. LHMSCs exhibit high proliferative
ability in long-term culture, and Wnt signaling has been
shown to modulate their growth [20]. In conditioned
media, LHMSCs are able to undergo osteogenic, chondro-
genic, and endothelial but not adipogenic differentiation.
Moreover, LHMSCs can differentiate into hepatocyte-like
cells, gaining hepatic functions such as production of
cytochrome P450, albumin, and urea. This implies the po-
tential of LHMSCs in cell therapy and pharmacotoxicolo-
gical testing [22, 27]. It is noteworthy that the proliferative
and differentiation capacities of MSCs decrease with age
[28, 29]. Thus, fetal LHMSCs may be superior. With re-
gard to their immune effects, LHMSCs express HLA-G
[30] and CD90 [22, 29], which regulate immune responses
by inhibiting T-cell proliferation [31]. Furthermore, CD90
is stably expressed in LHMSCs, suggesting that such cells
exert immunosuppressive effects [32, 33].
LHMSCs differ from other resident hepatic stem/pro-
genitor cells. Dormant liver progenitor cells are peripor-
tally located in the healthy liver and actively proliferate
after chronic liver injury or sub-massive liver cell loss
[34]. LHMSCs are spindle-shaped, whereas liver pro-
genitor cells are oval. Moreover, LHMSCs are negative
for CD117, CD34, and CK19, markers of liver progenitor
cells [21]. Hepatic stellate cells (HSCs) are another type
of stem/progenitor cell in the liver that acquire a
myofibroblast-like phenotype when activated. As is true
of LHMSCs, activated HSCs express CD133, a molecular
maker of stem/progenitor cells [35]. However, HSCs are
positive for NCAM, CK19 and HLA-class II membrane
markers [36], for which LHMSCs are negative. More-
over, chemokine levels differ markedly between LHMSCs
and HSCs: the former cells secrete higher levels of thera-
peutic and immune-modulatory cytokines, including
hepatocyte growth factor (HGF), interferon (IFN)-γ and
interleukin (IL)-10 [37].
Fig. 1 Comparison of the morphology of LHMSCs (a) and BMMSCs (b). Similar to BMMSCs, LHMSCs are spindle-shaped with ovoid nuclei. Both
cells are at passage 3. Original magnification: 100×
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Hepatic differentiation protocol
Iscove’s modified Dulbecco’s medium with sequential
cytokine supplements (Fig. 2) is the most frequently
used hepatic differentiation procedure.
In the initial induction step, MSCs are induced into
endodermal cells by epidermal growth factor (EGF) and
fibroblast growth factor (FGF). EGF stimulates prolifera-
tion of MSCs by binding to EGF receptor (EGFR) [38].
MSCs transfected with an EGF vector and stimulated by
Ca+ can differentiate into epithelial-like cells [39]. FGF,
which constitutes a family of at least seven closely re-
lated polypeptides with heparin-binding properties, plays
a pivotal role during the initial stage of endodermal
patterning [40]. Among these, FGF-4 and basic FGF are
used conventionally. Similar to EGF, FGF also increases
the proliferation rate of MSCs [41–43].
FGF, HGF, nicotinamide (NTA) and insulin-transferrin-
selenium (ITS) are commonly added to cultures to trigger
cell differentiation. HGF is a pleiotropic cytokine of mesen-
chymal origin involved in the regulation of proliferation, dif-
ferentiation, and chemotactic migration of MSCs [44, 45].
Ghaedi et al. [46] cultured adipose stem cells on HGF/colla-
gen I spots for 2 weeks and found increased expression of
hepatocyte-specific genes, indicating hepatic induction of
HGF. Interestingly, Forte et al. [45] showed that short-term
exposure of MSCs to HGF results in activation of the c-met
receptor and the downstream effectors, ERK1/2, p38,
MAPK, and PI3K/Akt, while long-term exposure resulted in
cytoskeletal rearrangement, cell migration, and marked in-
hibition of proliferation. ITS and NTA promote the prolifer-
ation and survival of primary hepatocytes [47, 48]. Chivu et
al. [49] compared the differentiation efficacy of various cyto-
kines, including HGF, ITS, dexamethasone and NTA, and
reported HGF and NTA to be the most potent inducers.
To induce further maturation, oncostatin M (OSM)
and dexamethasone are required, together with the
addition of FGF, ITS, and HGF. Zhou et al. [50] demon-
strated that HGF promoted a mid/late hepatic pheno-
type but failed to induce functional hepatocyte
maturation. Thus, a further maturation procedure is
needed. OSM is a member of the IL-6 subfamily that
plays an important role in progression from hepatocyte
development to liver maturation [51, 52]. A recent
study indicated that the hepatic induction effects of
OSM might be correlated with downregulation of sox
9 [53], which enforces proliferation and maintains the
pluripotency of stem/progenitor cells [54, 55]. Dexa-
methasone induces the expression of both HNF4 and
CCAAT/EBPα. Both transcription factors are essential
for hepatocyte differentiation [56]. Histone deacetylase
inhibitors, such as trichostatin A and sodium butyr-
ate, contribute to hepatic differentiation of stem cells
[57–60]. Notably, histone deacetylase inhibitors
enhance the expression of hepatocyte-specific genes
and functions [61] but decrease the adipogenic, chon-
drogenic, and neurogenic differentiation potential of
MSCs [62].
Although several hundred studies have demonstrated
the generation of hepatocyte-like cells, the procedure for
identifying a differentiated cell as a hepatocyte has not
been standardized. The following sequence of tests is
recommended to determine the generation of hepato-
cytes: 1) quantitative reverse transcription polymerase
chain reaction (PCR); 2) protein expression evaluation;
3) ultrastructural evaluation; 4) functional analysis; and
5) engraftment, differentiation, and functional repopula-
tion in vivo [63].
Fig. 2 Signaling pathways of LHMSC differentiation into hepatocytes
in vitro. Hepatic differentiation can be divided into three stages:
induction, differentiation and maturation. Sequential addition of
cytokines to the medium plays a vital role at each stage. DEX
dexamethasone, EBP enhancer binding protein, EGF epidermal
growth factor, EGFR epidermal growth factor receptor, ERK1/2
extracellular-signal-regulated kinase 1/2, FGF fibroblast growth factor,
HGF hepatocyte growth factor, HNF4 hepatocyte nuclear factor 4, ITS
insulin-transferrin-selenium, MAPK mitogen-activated protein kinase,
OSM oncostatin M, PI3K phosphoinositide 3-kinase, NTA nicotinamide
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Cell therapy for liver disorders
MSCs are considered ideal candidates for cell transplant-
ation due to their immunosuppressive, angiogenic, and
anti-inflammatory activities. We discuss the use of
LHMSCs and LHMSC conditioned medium (LHMSC-
CM) in animal models (Table 1) and the clinic.
Metabolic disorders
The liver has a capacity for biotransformation. Khuu et
al. [27] evaluated the abilities of differentiated LHMSCs
to synthesize glucose and to metabolize ammonia as well
as xenobiotics. These functions were enhanced after
hepatic induction, suggesting the feasibility of using
these cells as alternatives to mature hepatocytes for in
vitro toxicopharmacological screening. With respect to
the activity of phase II drug-metabolizing enzymes,
LHMSCs were transplanted into rodents with Crigler-
Najjar syndrome to correct hyperbilirubinemic
conditions [64]. Furthermore, Baruteau et al. [65]
demonstrated high L-phenylalanine hydroxylase (PAH)
expression and a marked increase in PAH activity in dif-
ferentiated LHMSCs, suggesting therapeutic potential
for phenylketonuria.
Pre-clinical safety experiments have not shown any in-
creasing risk of tumorigenicity, either in vitro or in vivo
[66]. Thus, these cells have been used in clinical trials.
Although LHMSCs exhibit immunosuppressive activ-
ities, immunosuppressants cannot be ignored. A patient
with glycogenosis type 1A was intraportally injected with
3 billion 111InDTPA-labeled cells and no signal was ob-
served in organs other than the liver, suggesting the
feasibility of the therapeutic use of LHMSCs [67]. The
engraftment potential of LHMSCs has been explored in pa-
tients with ornithine carbamoyltransferase deficiency [68]
(clinicaltrials.gov identifier NCT01765283, NCT02489292,
NCT02051049).
Liver regeneration
The liver is unique in terms of its regeneration ability.
Depending on the proliferation of residual mature hepa-
tocytes that re-enter the cell cycle and proliferate, nor-
mal liver weight can be re-established within 8–15 days
in humans (5–7 days in rodents) [69]. The two-thirds
partial hepatectomy rodent model is the classic model
used to study liver regeneration. Although LHMSCs
have been demonstrated to participate in liver regener-
ation [19, 70], the mechanisms involved have not been
clearly elucidated (Fig. 3).
The effect might be due to hepatic differentiation of
multipotent stem cells. In situ hepatic differentiation was
observed in transplanted mice, which supports this hy-
pothesis. Nevertheless, other data indicate that cells with
donor markers and liver-specific markers in the recipient
liver are a product of cell fusion rather than a real trans-
differentiation [71, 72].
Paracrine signaling is another possible explanation.
MSCs secrete various growth factors, cytokines, and
chemokines, of which CCL7, vascular endothelial growth
factor (VEGF), and CXC family members are involved in
anti-inflammatory responses, apoptosis prevention, and
angiogenesis [37]. Because secreted factors have no risk
of rejection or malignant transformation, LHMSC-CM
Table 1 Preclinical studies using HLMSCs or HLMSC-CM to treat liver diseases








LHMSCs 2.5 × 106 Rigler-Najjar
type I
syndrome
Gunn rats iv (portal vein) 6
months
Decrease in bilirubin level [64]
LHMSCs 1 × 106 20 %
hepatectomy
SCID mice ip 60 days Proliferation and differentiation of
LHMSCs in vivo
[66]




ip 56 days Proliferation and differentiation of
LHMSCs in vivo
[19]




2 days Enhanced liver regenerative
responses
[73]
LHMSCs 5 × 105 Liver fibrosis NOD/SCID/IL-2Rγ
(null) mice
iv (tail vein) 8
weeks
No benefits observed [87]
LHMSCs 2 × 105 Acute liver
injury
SCID mice iv 30 days Proliferation of LHMSCs in vivo [22]
LHMSCs from liver graft
preservation fluids
1× 106 Acute liver
injury
NOD/SCID mice ip 4
weeks
Differentiation of LHMSCs in vivo [20]
MSCs, LHMSC-CM 2 × 106 (iv), 3 × 107 (ip),
5 × 105 or 2 × 105 (LP)
Acute liver
failure
SCID mice iv, ip, LP 21 days Increased survival rates, decrease
in liver metabolic enzymes and
ammonium
[81]
ip intrasplenic injection, iv intravenous injection, LHMSC liver-derived human mesenchymal stem cell, LHMSC-CM liver-derived human mesenchymal stem cell
conditioned medium, LP injection via liver parenchyma, MSC mesenchymal stem cell
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might be more beneficial than MSCs. In pre-clinical ex-
periments, the efficacy of application of LHMSC-
secreted factors in 70 % hepatectomized mice suggests
their potential use in patients undergoing extensive liver
resection or transplantation of small liver grafts [73].
The genetic influence of microvesicles (MVs) has also
been investigated. MVs are heterogeneous circular mem-
brane fragments that comprise two major populations:
exosomes and microparticles. Exosomes originate from
the exosomal compartment and are 30–100 nm in diam-
eter. In contrast, microparticles are released directly
from budding of the plasma membrane surface and are
100 nm to 1 μm in diameter. The biological significance
of MVs was largely overlooked for many years. Recently,
they have been recognized to carry proteins, micro-
RNAs, and mRNAs, and to play important roles in cell-
to-cell communication [74]. Quesenberry et al. [75] pro-
posed a novel concept known as areas of influence,
which refers to the influence of complex effectors on the
lability of the stem cell phenotype. Areas of influence in-
clude cell cycle passage, complex interactions with stro-
mal cells, and MV-mediated cell-to-cell transfer of
genetic information. Stem cells undergo functional and
phenotypic changes after receiving genetic information,
transferred by MVs, from injured cells. Moreover, feed-
back from stem cells alters the functions of target cells,
suggesting that stem cells repair damaged tissues with-
out directly replacing parenchymal cells [76, 77]. The
protective effect of MVs from LHMSCs was confirmed
by Herrera et al., who reported that MVs shuttled
mRNAs into hepatocytes of hepatectomized rats and ac-
celerated hepatic regeneration [78].
Acute liver injury
Acute liver failure, a lethal clinical syndrome, is charac-
terized by rapid development of hepatocellular dysfunc-
tion with diffuse intrahepatic infiltration of inflammatory
cells and massive multilobular necrosis. Based on their
release of trophic and immunomodulatory factors, MSCs
are commonly used in the treatment of acute liver in-
jury. Parekkadan et al. [79, 80] postulated that soluble
factors present in MSC-conditioned medium (IL-6,
VEGF, and HGF) were responsible for both local and
systemic therapeutic effects. Herrera et al. [81] reported
that LHMSCs also significantly prevented death in a fatal
model of fulminant liver failure. They further stated that
the therapeutic effect was due to a paracrine
mechanism.
Liver cirrhosis
Liver cirrhosis, the most advanced stage of fibrosis, con-
notes not only more scarring than that from fibrosis
alone, but also distortion of the liver parenchyma associ-
ated with septae and nodule formation, altered blood
flow, and risk of liver failure [82]. The activation of
HSCs is a pivotal event in the development of liver cir-
rhosis [12]. It seems that the anti-fibrotic effects of
MSCs in liver cirrhosis are based on the release of fac-
tors that alter the function of HSCs. HGF is expressed
highly in LHMSCs. Overexpression of HGF promotes
HSC apoptosis [83, 84]. Moreover, HGF is associated
with hepatogenesis. The plasma HGF level increases
considerably after partial hepatectomy [85]. Compared
with BMMSC conditioned medium, the HGF level was
~50-fold higher in LHMSC-CM [81]. IL-10 and tumor
necrosis factor (TNF)-α also reduce the proliferation of
HSCs and synthesis of collagen type I [37, 79]. More-
over, LHMSCs can secrete IFN-γ, inducing anti-fibrotic
effects [86].
However, in a murine model of CCl4-induced liver fi-
brosis, intravenous administration of LHMSCs failed to
improve liver function [87] and the injected cells propa-
gated in various tissues; less effective transplantation
may explain the failure. To promote MSCs homing to
the liver, the following approaches can be employed: 1)
direct injection, such as injection via the portal vein,
spleen, and liver parenchyma; and 2) use of MSCs modi-
fied by liver-specific receptors.
Fig. 3 Possible mechanisms of liver regeneration related to LHMSCs. LHMSCs promote regeneration of the remaining liver, likely through the
following mechanisms: replacement of injured hepatocytes, secretion of beneficial factors, and genetic modification
Wang et al. Stem Cell Research & Therapy  (2016) 7:71 Page 5 of 8
Conclusions
As a novel type of MSC, LHMSCs exhibit general prop-
erties of MSCs, including self-renewal, multipotent dif-
ferentiation and immunomodulation. Compared with
other types of MSCs, LHMSCs have several advantages,
such as more secretion of protective factors. However,
the following problems must be addressed: 1) how to in-
duce differentiation of LHMSCs into functional cells that
are more similar to primary hepatocytes; 2) identifying
the criteria for evaluation of the degree of hepatic differ-
entiation of LHMSC-derived cells; 3) improvement of
the efficiency of cell homing to the liver after transplant-
ation; 4) determining the number of cells required for
various diseases; and 5) identifying the possible risks of
LHMSC transplantation. Thus, further studies are
needed to characterize LHMSCs, improve the efficacy of
hepatic differentiation, and validate their therapeutic po-
tential in liver diseases.
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